Merck Signs Sale Agreement with Santen for Merck’s Ophthalmology Products in Japan and Key Markets in Europe and Asia Pacific | Merck Newsroom Home

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it signed an agreement for Santen Pharmaceutical Co., Ltd. (Santen) to purchase Merck’s ophthalmology products, COSOPT^® (dorzolamide hydrochloride – timolol maleate ophthalmic solution), COSOPT PF^® (dorzolamide hydrochloride-timolol maleate ophthalmic solution) 2%/0.5%, TRUSOPT^® (dorzolamide hydrochloride ophthalmic solution) sterile ophthalmic solution 2%, TRUSOPT PF^® (dorzolamide hydrochloride ophthalmic solution) preservative-free, TIMOPTIC^® (timolol maleate ophthalmic solution), TIMOPTIC PF® (timolol maleate preservative free ophthalmic solution in unit dose dispenser), TIMOPTIC XE^® (timolol maleate ophthalmic gel forming solution), SAFLUTAN^® (tafluprost) and TAPTIQOM^® (tafluprost-timolol maleate ophthalmic solution, in development) in Japan and key markets in Europe and Asia Pacific. - See more at: http://www.mercknewsroom.com/news-release/corporate-news/merck-signs-sale-agreement-santen-mercks-ophthalmology-products-japan-an#sthash.mceNa0qr.dpuf



Merck Signs Sale Agreement with Santen for Merck’s Ophthalmology Products in Japan and Key Markets in Europe and Asia Pacific | Merck Newsroom Home